Crenae Therapeutics is dedicated to the development of ASPH inhibitors. These novel compounds have an extremely attractive toxicity profile, are highly effective at suppressing tumor metastasis, and have potential application against a large number of human and veterinary cancers.
Aspartyl(asparaginyl)-beta-hydroxylase (ASPH) is a cell surface displayed enzyme that is critical for embryological development, in particular for the invasion of the uterine wall. ASPH is not expressed in adult tissue, but is inappropriately activated by cancer cells to enhance invasion, migration and metastasis. Therefore, ASPH is an antimetastatic target, and ASPH inhibitors naturally have a lower toxicity profile than cytotoxic or antiproliferative anticancer therapeutics.
Crenae Therapeutics is developing small molecule therapeutics for the treatment of ASPH expressing cancers, including hepatocellular carcinoma, cholangiocarcinoma, breast, ovarian and lung cancer, and osteosarcoma. Beyond existing advanced rodent model systems, testing in canines leading to a canine veterinary therapeutic using the Minor Use Minor Species (MUMS) approval is an essential component of the Crenae Therapeutic approach, followed by demonstration of in human activity against an orphan cancer.
Our team is focused on the development and testing of specific clinical candidates. This development includes oral dosage form formulation, pharmacokinetic evaluation, and toxicity profiling.
High quality therapeutics, like ASPH inhibitors, begin with a vision. This vision is then embodied with a specific target, and molecules are carefully crafted from conception to have proper structure, ease of synthesis, solubility, bioavailability, and metabolic stability. These properties are utilized in the formulation, and collectively result in a superior pharmaceutical manufacturing process.
Crenae Therapeutics has licensed non-toxic, orally bioavailable ASPH inhibitors for development into veterinary, orphan and broad spectrum antimetastatic small molecule therapeutics. Multiple ASPH inhibiting chemotypes have been developed.
Modern precision medicine, including an anti-ASPH therapeutic, is critically dependent on biomarker detection and validation as an essential component for successful clinical trial demonstration of effectiveness. Crenae Therapeutics has licensed a proprietary technology for the detection of ASPH.
Crenae Therapeutics has a robust pipeline of alternative small molecule chemotypes and biotechnologies for treatment of ASPH expressing cancers. This robust pipeline mitigates risk, and enables alternative licensing strategies.
Please reach out to us with any concerns or special requests.
Feel free to send any documents to firstname.lastname@example.org.
Monday - Friday: 9am - 5pm
Saturday - Sunday: Closed